NASDAQ$SERA
Sera Prognostics Inc-A · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Reported financial results for the third quarter of 2024 ended September 30, 2024.
Sera Prognostics reported third quarter 2024 revenue of $29,000, a decrease from $42,000 in the same period of 2023. The net loss for the quarter was $7.9 million, compared to $7.2 million for the prior-year period.
- Data analysis for full PRIME study underway after database was locked in September and now seeking publication of results in connection with key pregnancy and maternal health conferences in early 2025.
- Awareness campaign activated with TV programs by Viewpoint with Dennis Quaid and Empowered with Meg Ryan.
- Beginning October 1, 2024, began enabling access to PreTRM® testing through the Company’s website, with home sample collection.
- Predictive analytics offering is now in beta testing, engaging women with informative reports based on the data from millions of pregnancy experiences, and personalized insights into pregnancies like theirs.
Headline financials
Revenue & EPS history
Sera Prognostics · Revenue · Quarterly
$29K
Forward guidance
The company is putting in place the key prerequisites for commercial success in anticipation of PRIME study results achieving publication and further illustrating the benefits of PreTRM capabilities and test-and-treat strategy.
Tailwinds
- Publication of PRIME study results.
- Expanded awareness and care guidelines.
- Multi-pronged approach to the maternal care market.
- Sales inflection in the business.
- More profitable margin and revenue growth.
Headwinds
- Net losses
- Need to raise more capital
- Revenues from the PreTRM Test representing substantially all Company revenues to date
- Need for broad scientific and market acceptance of the PreTRM Test
- Potential third-party payer coverage and reimbursement
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
-1.9%
Avg return
Earnings day
-3.5%
Avg return
5 days after
-3.3%
Avg return
30 days after
36%
8 / 22 earnings
Positive
+14.3%
Q3 2022
Best reaction
-11.7%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.7% | -8.0% | +18.1% | |
| Q4 2025 | -7.7% | +6.3% | +20.4% | |
| Q3 2025 | +1.7% | +8.5% | +19.0% | |
| Q1 2025 | -11.7% | -2.1% | -35.4% | |
| Q4 2024 | -5.1% | -2.2% | -17.9% | |
| Q3 2024 | -0.3% | -2.7% | -3.9% | |
| Q2 2024 | +0.0% | -1.2% | -2.2% | |
| Q1 2024 | +3.3% | -4.0% | -13.6% | |
| Q4 2023 | +3.4% | +1.1% | +7.7% | |
| Q3 2023 | -3.2% | -6.4% | +130.9% | |
| Q2 2023 | +0.8% | -10.1% | -39.9% | |
| Q1 2023 | -0.8% | -2.8% | -13.0% | |
| Q4 2022 | -10.0% | -9.5% | -22.3% | |
| Q3 2022 | +14.3% | +11.1% | -4.0% | |
| Q2 2022 | -4.1% | -6.3% | -27.3% | |
| Q1 2022 | -7.6% | -17.1% | -32.7% | |
| Q4 2021 | +3.6% | +0.3% | -39.3% | |
| Q3 2021 | +0.3% | -0.8% | -8.2% | |
| Q3 2020 | +0.3% | -0.8% | -8.2% | |
| Q2 2021 | -4.8% | -9.9% | +0.0% | |
| Q1 2021 | -4.8% | -9.9% | +0.0% | |
| Q4 2020 | -4.8% | -9.9% | +0.0% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro